{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:46:47Z","timestamp":1782172007683,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-007625, America"],"award-info":[{"award-number":["INV-007625, America"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006739","name":"Capital Foundation of Medical Development","doi-asserted-by":"publisher","award":["CFH 2022- 2Z- 40917"],"award-info":[{"award-number":["CFH 2022- 2Z- 40917"]}],"id":[{"id":"10.13039\/501100006739","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hua Medicine funding"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-71798-x","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T21:09:58Z","timestamp":1776805798000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A pharmacokinetic and pharmacodynamic drug-drug interaction study of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity: an open-label phase I trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7397-0865","authenticated-orcid":false,"given":"Huan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0691-5116","authenticated-orcid":false,"given":"Yuanhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingge","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6002-4846","authenticated-orcid":false,"given":"Jiayi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8936-6196","authenticated-orcid":false,"given":"Yu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5245-4379","authenticated-orcid":false,"given":"Yu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8217-0577","authenticated-orcid":false,"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Tracey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6192-3752","authenticated-orcid":false,"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0608-8192","authenticated-orcid":false,"given":"Dongyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"71798_CR1","doi-asserted-by":"crossref","unstructured":"Collaborators GBDD. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402, 203\u2013234 (2023).","DOI":"10.1016\/S0140-6736(23)01301-6"},{"key":"71798_CR2","first-page":"100690","volume":"33","author":"J Quan","year":"2023","unstructured":"Quan, J. et al. Potential health and economic impact associated with achieving risk factor control in Chinese adults with diabetes: a microsimulation modelling study. Lancet Reg. Health West Pac. 33, 100690 (2023).","journal-title":"Lancet Reg. Health West Pac."},{"key":"71798_CR3","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc24-S009","volume":"47","author":"American Diabetes Association","year":"2024","unstructured":"American Diabetes Association Professional Practice C. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024. Diab. Care 47, S158\u2013S178 (2024).","journal-title":"Diab. Care"},{"key":"71798_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/dom.13108","volume":"20","author":"E Cersosimo","year":"2018","unstructured":"Cersosimo, E., Johnson, E. L., Chovanes, C. & Skolnik, N. Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach. Diab. Obes. Metab. 20, 497\u2013507 (2018).","journal-title":"Diab. Obes. Metab."},{"key":"71798_CR5","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx, N. et al. ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur. Heart J. 44, 4043\u20134140 (2023).","journal-title":"Eur. Heart J."},{"key":"71798_CR6","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/dom.15370","volume":"26","author":"L Feng","year":"2023","unstructured":"Feng, L., Chen, C., Guo, Q., Chen, L. & Yang, W. Improvement of early-phase insulin secretion is an independent factor for achieving glycaemic control: a pooled analysis of SEED and DAWN study. Diab. Obes. Metab. 26, 745\u2013753 (2023).","journal-title":"Diab. Obes. Metab."},{"key":"71798_CR7","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1038\/s41467-023-36946-7","volume":"14","author":"L Chen","year":"2023","unstructured":"Chen, L. et al. A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity. Nat. Commun. 14, 1405\u20131413 (2023).","journal-title":"Nat. Commun."},{"key":"71798_CR8","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s40265-022-01813-0","volume":"82","author":"YY Syed","year":"2022","unstructured":"Syed, Y. Y. Dorzagliatin: First Approval. Drugs 82, 1745\u20131750 (2022).","journal-title":"Drugs"},{"key":"71798_CR9","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1111\/dom.13338","volume":"20","author":"XX Zhu","year":"2018","unstructured":"Zhu, X. X. et al. Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic beta-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection. Diab. Obes. Metab. 20, 2113\u20132120 (2018).","journal-title":"Diab. Obes. Metab."},{"key":"71798_CR10","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S2213-8587(18)30105-0","volume":"6","author":"D Zhu","year":"2018","unstructured":"Zhu, D. et al. Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Diab. Endocrinol. 6, 627\u2013636 (2018).","journal-title":"Lancet Diab. Endocrinol."},{"key":"71798_CR11","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41591-022-01802-6","volume":"28","author":"D Zhu","year":"2022","unstructured":"Zhu, D. et al. Dorzagliatin in drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial. Nat. Med 28, 965\u2013973 (2022).","journal-title":"Nat. Med"},{"key":"71798_CR12","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1111\/dom.15179","volume":"25","author":"JE Zeng","year":"2023","unstructured":"Zeng, J. E. et al. Diabetes remission in drug-naive patients with type 2 diabetes after dorzagliatin treatment: a prospective cohort study. Diab. Obes. Metab. 25, 2878\u20132887 (2023).","journal-title":"Diab. Obes. Metab."},{"key":"71798_CR13","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s40265-014-0298-1","volume":"74","author":"LJ Scott","year":"2014","unstructured":"Scott, L. J. Empagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs 74, 1769\u20131784 (2014).","journal-title":"Drugs"},{"key":"71798_CR14","doi-asserted-by":"publisher","first-page":"108050","DOI":"10.1016\/j.diabres.2020.108050","volume":"161","author":"WC Wu","year":"2020","unstructured":"Wu, W. C. et al. Progression of insulin resistance: a link between risk factors and the incidence of diabetes. Diab. Res Clin. Pr. 161, 108050\u2013108057 (2020).","journal-title":"Diab. Res Clin. Pr."},{"key":"71798_CR15","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1172\/JCI129188","volume":"129","author":"LI Hudish","year":"2019","unstructured":"Hudish, L. I., Reusch, J. E. & Sussel, L. Beta Cell dysfunction during progression of metabolic syndrome to type 2 diabetes. J. Clin. Invest 129, 4001\u20134008 (2019).","journal-title":"J. Clin. Invest"},{"key":"71798_CR16","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1080\/00325481.2020.1771047","volume":"132","author":"C Wysham","year":"2020","unstructured":"Wysham, C. & Shubrook, J. Beta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications. Postgrad. Med 132, 676\u2013686 (2020).","journal-title":"Postgrad. Med"},{"key":"71798_CR17","doi-asserted-by":"publisher","first-page":"641","DOI":"10.4093\/dmj.2021.0220","volume":"45","author":"SY Park","year":"2021","unstructured":"Park, S. Y., Gautier, J. F. & Chon, S. Assessment of insulin secretion and insulin resistance in human. Diab. Metab. J. 45, 641\u2013654 (2021).","journal-title":"Diab. Metab. J."},{"key":"71798_CR18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1109\/10.995680","volume":"49","author":"C Dalla Man","year":"2002","unstructured":"Dalla Man, C., Caumo, A. & Cobelli, C. The oral glucose minimal model: estimation of insulin sensitivity from a meal test. IEEE Trans. Biomed. Eng. 49, 419\u2013429 (2002).","journal-title":"IEEE Trans. Biomed. Eng."},{"key":"71798_CR19","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1111\/dom.14394","volume":"23","author":"M Schiavon","year":"2021","unstructured":"Schiavon, M. et al. Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1\/glucagon receptor agonist SAR425899 in comparison with liraglutide. Diab. Obes. Metab. 23, 1795\u20131805 (2021).","journal-title":"Diab. Obes. Metab."},{"key":"71798_CR20","unstructured":"U.S. Department of Health and Human Services FDA, Center for Drug Evaluation and Research (CDER). Statistical approaches to establishing bioequivalence guidance for industry. https:\/\/www.fda.gov\/media\/163638\/download. (2022)."},{"key":"71798_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.tjem.2018.08.001","volume":"18","author":"H Akoglu","year":"2018","unstructured":"Akoglu, H. User\u2019s guide to correlation coefficients. Turk. J. Emerg. Med 18, 91\u201393 (2018).","journal-title":"Turk. J. Emerg. Med"},{"key":"71798_CR22","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s40265-018-0937-z","volume":"78","author":"JE Frampton","year":"2018","unstructured":"Frampton, J. E. Empagliflozin: A Review in Type 2 Diabetes. Drugs 78, 1037\u20131048 (2018).","journal-title":"Drugs"},{"key":"71798_CR23","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.tem.2023.02.001","volume":"34","author":"G Di Giuseppe","year":"2023","unstructured":"Di Giuseppe, G. et al. First-phase insulin secretion: can its evaluation direct therapeutic approaches?. Trends Endocrinol. Metab. 34, 216\u2013230 (2023).","journal-title":"Trends Endocrinol. Metab."},{"key":"71798_CR24","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1111\/dom.13338","volume":"20","author":"XX Zhu","year":"2018","unstructured":"Zhu, X. X. et al. Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic \u03b2-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection. Diab. Obes. Metab. 20, 2113\u20132120 (2018).","journal-title":"Diab. Obes. Metab."},{"key":"71798_CR25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41580-020-00317-7","volume":"22","author":"JE Campbell","year":"2021","unstructured":"Campbell, J. E. & Newgard, C. B. Mechanisms controlling pancreatic islet cell function in insulin secretion. Nat. Rev. Mol. Cell Biol. 22, 142\u2013158 (2021).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"71798_CR26","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.5114\/amsad.2021.105314","volume":"6","author":"GS Papaetis","year":"2021","unstructured":"Papaetis, G. S. Empagliflozin therapy and insulin resistance-associated disorders: effects and promises beyond a diabetic state. Arch. Med Sci. Atheroscler. Dis. 6, e57\u2013e78 (2021).","journal-title":"Arch. Med Sci. Atheroscler. Dis."},{"key":"71798_CR27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S1262-3636(14)72689-8","volume":"40","author":"AJ Scheen","year":"2014","unstructured":"Scheen, A. J. & Paquot, N. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence. Diab. Metab. 40, 4\u201311 (2014).","journal-title":"Diab. Metab."},{"key":"71798_CR28","first-page":"1619","volume":"10","author":"H Xu","year":"2016","unstructured":"Xu, H. et al. zSafety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study. Drug Des. Dev. Ther. 10, 1619\u20131626 (2016).","journal-title":"Drug Des. Dev. Ther."},{"key":"71798_CR29","first-page":"e36916","volume":"103","author":"Y Wu","year":"2024","unstructured":"Wu, Y., Wang, K., Su, J. & Liu, X. Efficacy and safety of dorzagliatin, a novel glucokinase activators, in the treatment of T2DM: A meta-analysis of randomized controlled trials. Medicines 103, e36916\u2013e36926 (2024).","journal-title":"Medicines"},{"key":"71798_CR30","doi-asserted-by":"publisher","first-page":"154892","DOI":"10.1016\/j.metabol.2021.154892","volume":"125","author":"L Mastrototaro","year":"2021","unstructured":"Mastrototaro, L. & Roden, M. Insulin resistance and insulin sensitizing agents. Metabolism 125, 154892\u2013154906 (2021).","journal-title":"Metabolism"},{"key":"71798_CR31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1530\/EC-20-0082","volume":"9","author":"Y Goto","year":"2020","unstructured":"Goto, Y. et al. Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use. Endocr. Connect 9, 599\u2013606 (2020).","journal-title":"Endocr. Connect"},{"key":"71798_CR32","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1172\/JCI70704","volume":"124","author":"A Merovci","year":"2014","unstructured":"Merovci, A. et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J. Clin. Invest 124, 509\u2013514 (2014).","journal-title":"J. Clin. Invest"},{"key":"71798_CR33","doi-asserted-by":"publisher","first-page":"150","DOI":"10.2337\/diabetes.50.1.150","volume":"50","author":"E Breda","year":"2001","unstructured":"Breda, E., Cavaghan, M. K., Toffolo, G., Polonsky, K. S. & Cobelli, C. Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity. Diabetes 50, 150\u2013158 (2001).","journal-title":"Diabetes"},{"key":"71798_CR34","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.2337\/db13-1198","volume":"63","author":"C Cobelli","year":"2014","unstructured":"Cobelli, C. et al. The oral minimal model method. Diabetes 63, 1203\u20131213 (2014).","journal-title":"Diabetes"},{"key":"71798_CR35","doi-asserted-by":"publisher","first-page":"20","DOI":"10.2337\/dc24-S002","volume":"47","author":"American Diabetes Association","year":"2024","unstructured":"American Diabetes Association Professional Practice C. 2. Diagnosis and classification of diabetes: standards of care in diabetes-2024. Diab. Care 47, 20\u201342 (2024).","journal-title":"Diab. Care"},{"key":"71798_CR36","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.2337\/dc10-0351","volume":"33","author":"R Retnakaran","year":"2010","unstructured":"Retnakaran, R. et al. Beta-cell function declines within the first year postpartum in women with recent glucose intolerance in pregnancy. Diab. Care 33, 1798\u20131804 (2010).","journal-title":"Diab. Care"},{"key":"71798_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cccn.2005.04.002","volume":"359","author":"AR Henderson","year":"2005","unstructured":"Henderson, A. R. The bootstrap: a technique for data-driven statistics using computer-intensive analyses to explore experimental data. Clin. Chim. Acta 359, 1\u201326 (2005).","journal-title":"Clin. Chim. Acta"},{"key":"71798_CR38","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10928-019-09632-9","volume":"46","author":"U Arshad","year":"2019","unstructured":"Arshad, U., Chasseloup, E., Nordgren, R. & Karlsson, M. O. Development of visual predictive checks accounting for multimodal parameter distributions in mixture models. J. Pharmacokinet. Pharmacodyn. 46, 241\u2013250 (2019).","journal-title":"J. Pharmacokinet. Pharmacodyn."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71798-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71798-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71798-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T22:50:09Z","timestamp":1782168609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71798-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["71798"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-71798-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors L.C., L.G.F., J.Y.Z., Y.S., Y.Z., and X.L. are employees of Hua Medicine. The remaining authors declare that they have no competing financial or nonfinancial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5520"}}